CRP and Venous thrombosis: Later, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) reported that a steady dose of canakinumab, an anti-inflammatory drug, reduced major adverse cardiovascular events (MACEs) among patients with a history of myocardial infarction (MI) and lowered the levels of c-reactive proteins (CRP) [7].